πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 39 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 12338274

Anti-VEGF protein compositions and methods for producing the same

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jun 24 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12319728

Anti-VEGF protein compositions and methods for producing the same

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jun 03 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 29 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12209120

Activatable anti-VEGF scFv

The Regents of the University of California Β· Granted Tue Jan 28 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 23 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12202883

Anti-VEGF protein compositions and methods for producing the same

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jan 21 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12116622

Methods of associating genetic variants with a clinical outcome in patients suffering from

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Oct 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12077570

Anti-VEGF protein compositions and methods for producing the same

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Sep 03 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12054533

Anti-VEGF protein compositions and methods for producing the same

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Aug 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12054532

Anti-VEGF protein compositions and methods for producing the same

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Aug 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12049489

Anti-VEGF protein compositions and methods for producing the same

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jul 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12012445

Anti-VEGF protein compositions and methods for producing the same

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jun 18 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 13 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12012444

Anti-VEGF protein compositions and methods for producing the same

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jun 18 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 13 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11958894

Anti-VEGF protein compositions and methods for producing the same

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Apr 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11938226

Abiotic anti-VEGF nanoparticle

The Regents of the University of California Β· Granted Tue Mar 26 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11769597

Methods of associating genetic variants with a clinical outcome in patients suffering from

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Sep 26 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 21 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11753459

Anti-VEGF protein compositions and methods for producing the same

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Sep 12 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11732025

Anti-VEGF protein compositions and methods for producing the same

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Aug 22 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 17 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11649273

Anti-VEGF protein compositions and methods for producing the same

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue May 16 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 11 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11548932

Anti-VEGF protein compositions and methods for producing the same

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jan 10 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11542317

Anti-VEGF protein compositions and methods for producing the same

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jan 03 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11524053

Methods and compositions for treatment of angiogenic disorders using anti-VEGF agents

The Regents of the University of California Β· Granted Tue Dec 13 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 08 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11519020

Methods of associating genetic variants with a clinical outcome in patients suffering from

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Dec 06 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 01 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11505594

Anti-VEGF protein compositions and methods for producing the same

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Nov 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11505593

Anti-VEGF protein compositions and methods for producing the same

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Nov 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11485770

Anti-VEGF protein compositions and methods for producing the same

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Nov 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted